WO2002098344A1 - Compositions antithrombotiques et instruments medicaux contenant lesdites compositions - Google Patents
Compositions antithrombotiques et instruments medicaux contenant lesdites compositions Download PDFInfo
- Publication number
- WO2002098344A1 WO2002098344A1 PCT/JP2002/005542 JP0205542W WO02098344A1 WO 2002098344 A1 WO2002098344 A1 WO 2002098344A1 JP 0205542 W JP0205542 W JP 0205542W WO 02098344 A1 WO02098344 A1 WO 02098344A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ammonium salt
- heparin
- antithrombotic
- aliphatic groups
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2067/00—Use of polyesters or derivatives thereof, as moulding material
Definitions
- Antithrombotic composition and medical device having the same
- the present invention relates to antithrombotic compositions.
- the antithrombotic composition of the present invention imparts an excellent antithrombotic property to a medical device without impairing the original function of the medical device by being applied to the blood contact surface of the medical device used in contact with blood. be able to.
- the present invention relates to (1) an antithrombotic composition capable of imparting long-term excellent antithrombotic and antibacterial properties to medical devices, and (2) conditions in which blood flows extremely rapidly and the blood moves rapidly.
- the present invention relates to an antithrombotic composition capable of imparting a long-term excellent antithrombotic property to a medical device intended for use below.
- the present invention also relates to a medical device having the antithrombotic composition.
- medical devices eg, blood circuit tubes, sampling monitor tubes, intra-aortic balloon pumps, artificial heart blood pumps, angiographic catheters, artificial lungs, venous reservoirs, artificial kidneys.
- the technology that imparts antithrombotic properties to the surface that comes into contact with blood in order to prevent blood from coagulating has been developed and put into practical use.
- the main consideration for improving the antithrombotic properties of medical devices has been to fix heparin or a heparin derivative, which has an anticoagulant effect, on the blood contact surface of the medical device by any method. This is a technique for imparting thrombotic properties.
- heparin or a heparin derivative As a method of introducing heparin or a heparin derivative to the blood contact surface of a medical device, various functional groups are introduced into heparin or a heparin derivative, and the heparin or heparin derivative is introduced onto a substrate of the blood contact surface of the medical device.
- Japanese Patent Application Laid-Open No. 4-197264 discloses that an amino group of heparin is covalently bonded to one terminal glycidyl group of polyethylene glycol diglycidyl ether, and then the other terminal glycidyl group is added.
- a method for covalently bonding to an amino group introduced on a substrate is disclosed.
- JP-A-58-147404 discloses that after a free terminal aldehyde group generated by depolymerizing heparin is covalently bonded to an amino group on a substrate on a blood contact surface of a medical device, A method for stabilizing the covalent bond by a reduction reaction is disclosed.
- the negative charge (sulfonate group or aminosulfonate group) of heparin or a heparin derivative can be reduced by the use of ammonium salt or phosphonium salt.
- a method has also been proposed in which an organic cation compound is combined to form a complex that is insoluble in water and soluble in an organic solvent, and is coated on a medical device.
- Japanese Patent Publication No. 48-13341 discloses that heparin is reacted with a cationic surfactant to prepare a heparin complex which is insoluble in water and soluble in an organic solvent.
- a method is disclosed in which a solution dissolved in a solvent is applied to a blood contact surface of a medical device and then dried to impart antithrombotic properties.
- ammonium salts such as alkyltrimethylammonium chloride and dilauryldimethylammonium chloride are mentioned as cationic surfactants.
- cationic surfactants it has been found that the complex of these ammonium salt and heparin elutes early when exposed to blood, and the antithrombotic property disappears in a short time.
- Japanese Patent Publication No. 48-13341 also discloses a long-chain alkyl group of penzalkonium salt (an ammonium salt having one long-chain alkyl group, two methyl groups and one benzyl group) as a solution to this problem.
- penzalkonium salt an ammonium salt having one long-chain alkyl group, two methyl groups and one benzyl group
- a complex of benzyl dimethyl stearyl ammonium salt having 18 carbon atoms and heparin (corresponding to Comparative Example 6 of the present application) is also disclosed.
- the problem of loss of antithrombotic properties could be improved to some extent.
- the problem of imparting excellent antithrombotic properties over a sufficiently long period cannot be solved.
- J. Biomater. Sci. Polymer Edn, vol. 6 contains a combination of heparin and dioctyldecyldimethylammonium bromide for the purpose of imparting excellent antithrombotic properties to medical devices over a long period of time.
- An ionic complex (corresponding to Comparative Example 7 of the present application) is described.
- heparin is applied to the surface of the medical device for a long time because the organic cation compound (dioctadecyldimethylammonium bromide) bound to heparin has a very high hydrophobicity.
- the problem with the ionic complex of heparin-organic cation compound that has been studied so far is that when an organic cation compound that is too hydrophilic is used (for example, a water-soluble ammonium salt such as a benzalkonium salt) is used. Is that heparin elutes in a short time, so that antithrombotic properties cannot be maintained for a long time.
- organic cation compounds that are too hydrophobic for example, dioctyldecyldimethylammonium amide
- the anticoagulant activity of heparin was suppressed, and sufficient performance could not be exhibited.
- heparin or heparin derivative is eluted into blood in a short time, or heparin or heparin derivative is significantly suppressed from being eluted.
- the zeolite complex has an appropriate balance between hydrophilicity and hydrophobicity.
- the present inventors have developed four aliphatic alkyl groups.
- the balance between hydrophilicity and water-phobicity of the ionic complex is adjusted by forming an ionic complex in which two kinds of ammonium salts having different total numbers of carbon are combined with heparin or a heparin derivative.
- the present inventors have proposed that at least two ammonium salts (dimethyldidodecyl ammonium salt and at least two alkyl groups having 30 to 38 carbon atoms and 10 or more carbon atoms)
- An ionic complex (ammonium salt) with heparin or a heparin derivative (corresponding to Comparative Examples 4 and 5 of the present application) was developed, and it was found that this could solve the above-mentioned problems [Patent No. 3228409 (Japanese Patent Application Laid-Open No. -164882)].
- the coating composition containing the ionic complex described in the above-mentioned Patent No. 3228409 has a blood flow rate that is not so fast as compared with a conventional heparin coating material. When applied to the medical device used (catheter, etc.), it exhibits extremely high antithrombotic properties.
- the above-mentioned ionic complex has been used in contact with blood for a long period of time, and its use has increased in recent years. For example, it has been found that antithrombotic properties are not yet sufficient for use in implantable artificial hearts and artificial organs such as auxiliary artificial hearts installed outside the body.
- coating using the composition containing the ionic complex described above when exposed to a rapid flow of blood and a violent movement, causes heparin to quickly flow into the blood, and thus is not suitable for a long time. It was difficult to maintain good antithrombotic properties.
- an antithrombotic composition capable of imparting long-term excellent antithrombotic properties even for medical devices intended to be used under such severe conditions.
- the antithrombotic property itself is lower than the material disclosed in the above-mentioned Patent No. 3228409 by the present inventors.
- antithrombotic compositions having antibacterial properties in addition to antithrombotic properties are also available. Also needed.
- An object of the present invention is to provide an antithrombotic composition capable of imparting a long-term excellent antithrombotic property to a medical device.
- An object of the present invention is to provide an antithrombotic composition capable of imparting long-term excellent antithrombotic and antibacterial properties to a medical device.
- Another object of the present invention is to provide a medical device intended to be used under conditions in which blood flows extremely fast and in which the blood moves rapidly, and can provide an excellent antithrombotic property over a long period of time. It is to provide a thrombotic composition.
- the present inventors have achieved an antithrombotic composition comprising an ionic complex formed from an organic cation mixture and heparin or a heparin derivative, wherein the organic cation mixture is:
- An antithrombotic composition that is a mixture of at least two ammonium salts has been found to be useful.
- the present inventors use the antithrombotic composition, wherein as the organic cation mixture, a mixture of (a) a water-soluble ammonium salt and (b) a water-insoluble ammonium salt is used.
- the present inventors have found that in the above antithrombotic composition, by using a mixture of the specific ammonium salts (c) and (d) described in detail below as an organic cation mixture, blood can flow extremely quickly. It has also been found that medical devices intended to be used under severe movement conditions can be provided with long-term excellent antithrombotic properties.
- the present invention is as follows.
- An antithrombotic composition comprising an ionic complex formed from an organic cation mixture and heparin or a heparin derivative,
- the antithrombotic composition wherein the organic cation mixture is a mixture of at least two kinds of ammonium salts.
- the organic cation mixture is a didodecyl dimethyl ammonium salt and an ammonium salt having four aliphatic groups, wherein the carbon atoms of the four aliphatic groups are A mixture with at least one ammonium salt selected from ammonium salts having a total number of 30 to 38 and two of the four aliphatic groups each being an alkyl group having at least 10 carbon atoms. Except in some cases. ]
- the present invention includes the following (1) and (2).
- An antithrombotic composition containing an ionic complex formed from an organic cation mixture and heparin or a heparin derivative
- organic cation mixture is a mixture of at least one (a) an ammonium salt soluble in water and at least one (b) an ammonium salt insoluble in water;
- An antithrombotic composition comprising an ionic complex formed from an organic zinc mixture and heparin or a heparin derivative
- organic cation mixture is a mixture of at least one kind of an ammonium salt (c) and at least one kind of an ammonium salt (d) shown below.
- an ammonium salt having four aliphatic groups bonded, wherein the total number of carbon atoms of the four aliphatic groups is 40 or more, and at least two aliphatic groups each have 12 or more carbon atoms.
- An ammonium salt which is an aliphatic alkyl group of
- ammonium salt having four aliphatic groups bonded, wherein two of the four aliphatic groups are each an aliphatic alkyl group having 3 or less carbon atoms, and the remaining two are each having 1 carbon atom.
- Ammonium salts which are 0 to 14 aliphatic alkyl groups.
- the present invention is also a medical device wherein the antithrombotic composition is coated on at least a part of a blood contact surface.
- ammonium salt used in the present invention is, for example, a salt with a halogen such as fluorine, chlorine, bromine, iodine or the like, and is preferably ammonium chloride or ammonium bromide.
- antithrombotic particularly refers to a case where blood comes into contact with the surface of a medical device or the like. Means that it is difficult to coagulate when formed, and hard to form a thrombus.
- the “antithrombotic composition containing the ionic complex” and the “antithrombotic composition” according to the present invention include, besides the ionic complex formed from the organic cation mixture and heparin or heparin derivative, It may contain an ionic complex formed from an organic cation mixture other than the above and heparin or a heparin derivative.
- a bioactive substance such as an antibacterial substance, a polymer substance serving as a binder,
- other additives may be contained in a range that does not substantially affect the properties of the ionic complex.
- the antithrombotic composition of the present invention is an organic cation mixture which is a mixture of at least one (a) water-soluble ammonium salt and at least one (b) water-insoluble ammonium salt. Is characterized by containing an ionic complex obtained by binding to a heparin or a heparin derivative.
- Such antithrombotic compositions include: (b) a water-insoluble ammonium salt that strongly retains heparin or a heparin derivative on the blood contact surface of a medical device, while (a) a water-soluble ammonium salt
- the salt suitably imparts a long-lasting antithrombotic property to the medical device because the salt prevents the ionic complex from being excessively biased toward hydrophobicity and moderately regulates the release rate of heparin or a heparin derivative.
- the antithrombotic composition of the present invention provides (a) a water-soluble ammonium salt that is slowly released into blood and exhibits its antibacterial properties, thereby preventing bacterial adhesion and propagation on medical devices.
- a water-soluble ammonium salt that is slowly released into blood and exhibits its antibacterial properties, thereby preventing bacterial adhesion and propagation on medical devices.
- various complications due to bacterial infection can be prevented.
- the "antibacterial property" in the present invention means to inhibit (preferably reduce) the generation, growth and proliferation of bacteria.
- Examples of (a) a water-soluble ammonium salt contained in the organic cation mixture used in the present invention include benzethonium salt and benzalkonium salt, such as decylbenzyldimethylammonium salt and dodecylpentyldimethylamine.
- Aqueous solution of salt mixture oval Disinfection aqueous solution commercially available under trade names such as benzophenone
- pentazenium salt and the like, and more preferably dodecyl pendenyl dimethyl ammonium bromide, benzethonium chloride and tetradecyl pendenyl dimethyl ammonium chloride.
- the amount of the (a) water-soluble ammonium salt used is determined by the total weight of the organic cation mixture [that is, the total weight of (a) the water-soluble ammonium salt and (b) the water-insoluble ammonium salt]
- the amount is usually 5 to 70% by weight, preferably 10 to 50% by weight, and more preferably 15 to 30% by weight.
- the anti-thrombotic property of the medical device will be low because the ionizable complex is too hydrophobic and it will be difficult to release heparin, and the medical device will have sufficient antibacterial properties. It is not preferable because it cannot be done.
- the (b) ammonium salt insoluble in water in the organic cation mixture used in the present invention includes an ammonium salt having four aliphatic groups bonded, and more specifically, an ammonium salt having four aliphatic groups bonded thereto.
- ammonium salts in which two of them are each an aliphatic alkyl group having 12 or more carbon atoms, and ammonium salts in which three of the four aliphatic groups are each an aliphatic alkyl group having 10 or more carbon atoms are preferred.
- insoluble in water in the present invention means that when a mixture containing 1% ammonium salt in pure water at 40 ° C., which is close to the body temperature, is stirred, the mixture does not become a transparent homogeneous solution, This means that the ammonium salt becomes oily and separates from water or remains dispersed and cloudy.
- ammonium salt in which two of the four aliphatic groups are each an aliphatic alkyl group having 12 or more carbon atoms in the present invention include, for example, didodecyldimethyl ammonium salt, and “ditetradecyldimethyl ammonium salt”.
- ditetradecyl dimethyl ammonium salt dihexadecyl dimethyl ammonium salt, dimethyl dipalmityl ammonium salt and dioctyl decyl dimethyl ammonium salt, and more preferably Tetradecyldimethylammonium bromide, dioctyl decyldimethylammonium bromide, and dimethyl dipalmitylammonium bromide.
- Examples of the “ammonium salt in which three of the four aliphatic groups are each an aliphatic alkyl group having 10 or more carbon atoms” in the present invention include, for example, tridecylmethylammonium salt and tridodecylmethylammonium salt. , Tritetradecylmethylammonium salt, trihexadecylmethylammonium salt, trioctadecylammonium salt, trieicosanylmethylammonium salt, and the like, and preferably tridodecylmethylammonium salt, It is a decyl methyl ammonium salt.
- the antithrombotic composition of the present invention is (c) an ammonium salt having at least one aliphatic group bonded thereto, wherein the total number of carbon atoms of the four aliphatic groups is 40 or more;
- the mixture is characterized by containing an ionic complex bound to a heparin or heparin derivative.
- an ionic complex is characterized in that the ammonium salt of the above (C) has higher water-phobicity than before and retains heparin or a heparin derivative more strongly on the surface of the medical device, while the ammonium salt of the above (d) However, it controls the release rate of heparin or heparin derivative moderately by preventing the ionic complex from being biased too hydrophobic. Therefore, the antithrombotic composition of the present invention is coated on a medical device (for example, an artificial organ such as an artificial heart) which is intended to be used under conditions where blood flow is fast and the movement is rapid. Even in such cases, excellent antithrombotic properties can be maintained over a long period of time.
- a medical device for example, an artificial organ such as an artificial heart
- an amino group having four aliphatic groups bonded thereto A monium salt wherein the total number of carbon atoms of the four aliphatic groups is 40 or more and at least two aliphatic groups are each an aliphatic alkyl group having 12 or more carbon atoms ''
- dieicosanyl dimethyl ammonium salt, dieicosanyl getyl ammonium salt, didocosyl dimethyl ammonium salt, ditetraeicosanyl dimethyl ammonium salt, tritetradecyl methyl ammonium salt, Trihexadecylmethylammonium bromide and the like are preferred, and dieicosanyldimethylammonium bromide, dieicosanylgetylammonium bromide and didocosanyldimethylammonium bromide are preferred.
- an ammonium salt having four aliphatic groups bonded wherein two of the four aliphatic groups each have an aliphatic alkyl group having 3 or less carbon atoms. And the remaining two are each an aliphatic alkyl group having 10 to 14 carbon atoms, such as didodecyldimethylammonium salt, didedecyldimethylammonium salt, didodecyl Getyl ammonium salt, ditetradecyl dimethyl ammonium salt, didecyl getyl ammonium salt, didodecyl dipropyl ammonium salt, didecyl dipropyl ammonium salt, and the like.
- the weight ratio between (c) and (d) is preferably from 1: 1 to 10: 1, and more preferably from 1: 1 to 5: 1.
- Heparin or a heparin derivative can be used for the ionic complex used in the present invention.
- heparin derivatives include, but are not limited to, heparin sodium, heparin potassium, heparin lithium, heparin calcium, heparin zinc, low molecular weight heparin, and epoxidized heparin.
- the material of the medical device substrate all materials commonly used can be used, for example, (for example, polyvinyl chloride, polycarbonate,
- the antithrombotic composition of the present invention is applied to the blood contact surface of a medical device by, for example, the following method, but is not limited to these methods.
- an organic cation mixture and heparin or a heparin derivative are stirred and mixed in a solvent to obtain a precipitate containing an ionic complex.
- the precipitate is collected and washed to remove unreacted heparin or heparin derivative and ammonium salt, and then the residue is purified by a known method to obtain an ionic complex.
- This ionic complex is dissolved in an organic solvent to obtain a solution.
- This solution is applied to the blood contacting surface of the medical device by the method described below, and then the solvent is dried and removed, whereby the surface can be provided with optimized antithrombotic properties. '
- examples of a method of applying the above solution to the surface of the medical device include a dipping method, a method of spraying a spray, and a method of applying with a brush or the like, but are not limited to these methods.
- the organic solvent used in the present method is not particularly limited as long as it does not impair the antithrombotic property of the ionic complex and does not damage the substrate surface of the medical device as much as possible.
- THF tetrahydrofuran
- 1,4-dioxane 1,4-dioxane
- cyclohexanone N, N-dimethyl
- Examples include formamide, N, N-dimethylacetamide, and N-methylpyrrolidone.
- the antithrombotic composition of the present invention comprises: Apply the solution dissolved in blood to the blood contact surface of the medical device, dry and remove the organic solvent, and then apply an aqueous solution of heparin or heparin derivative to contain the zwitterionic complex on the blood contact surface After the antithrombotic composition is formed, the composition can also be applied by a method of drying and removing water.
- the same organic solvent as that described in Method 1 can be used as the organic solvent.
- Example 2 15 parts by weight of penzetonium chloride (manufactured by Aldrich) and 72 parts by weight of dioctyl decyl dimethylammonium bromide (manufactured by Tokyo Chemical Industry) were dissolved in 150 parts by weight of methanol and the same as in Example 1.
- Example 4 20 parts by weight of tetradecyl benzylammonium chloride (manufactured by Tokyo Chemical Industry) and 40 parts by weight of dimethyldipalmitylammonium bromide (manufactured by Tokyo Chemical Industry) were dissolved in 150 parts by weight of methanol. By the same method as in 1, the ionic complex (Example 3) used in the present invention was obtained.
- Example 1 60 parts by weight of tridodecylmethylammonium bromide (manufactured by Tokyo Chemical Industry) was dissolved in 150 parts by weight of methanol, and an ionic complex (Comparative Example 1) was obtained in the same manner as in Example 1. Was.
- Example 2 65 parts by weight of dioctyl decyl dimethyl ammonium bromide (manufactured by Tokyo Chemical Industry) was dissolved in 150 parts by weight of methanol, and an ionic complex (Comparative Example 2) was obtained in the same manner as in Example 1. Was.
- Example 3 30 parts by weight of dodecylpentyldimethylammonium chloride (manufactured by Tokyo Chemical Industry) was dissolved in 50 parts by weight of methyl alcohol, and an ionic complex (Comparative Example 3) was prepared in the same manner as in Example 1. Obtained.
- a saline solution heated to 37 ° C was injected into a tube pump coated with the above ionic complex into a mouth pump. After 1 day, samples were collected. Collected sample was filled with bovine blood with citrate and incubated at 37 ° C. Next, a 1 / 40N calcium chloride solution was added to the sample to initiate blood coagulation. Three minutes later, trisodium citrate was added to the samples to stop blood clotting. Coagulated blood (thrombus) was collected, lyophilized and weighed. The results are shown in the "antithrombotic" column of Table 1.
- the numerical value in the column of ⁇ antithrombotic properties '' indicates that the amount of thrombus formed in the glass tube having the same diameter as that of the polyvinyl chloride tube used in this test was 1 in the polyvinyl chloride tube.
- the relative weight ratio of the determined thrombus amount is shown.
- compositions containing the ionic complexes obtained in Examples 1 to 3 and Comparative Examples 1 to 3 were evaluated by the following methods. A series of operations in this test were all performed aseptically.
- a Pseudomonas aeruginosa solution (hereinafter referred to as a bacterial stock solution) adjusted to a concentration of about 1 ⁇ 10 7 cells / ml with a broth solution diluted 50-fold with sterile physiological saline was prepared.
- the number of bacteria in this stock solution was measured as follows. Plated 10 4 fold dilution 100 1 bacteria stock solution on a nutrient agar plate, the number of colonies was counted Pseudomonas aeruginosa formed after 24 hours. Assuming that the number of these colonies is N, the concentration C of the bacterial stock solution is
- This bacterial stock solution 100/1 was diluted with broth solution (40-fold dilution with sterile physiological saline solution) to adjust the total volume to 40 ml (hereinafter, this solution is referred to as immersion stock solution).
- EOG-sterilized vinyl chloride film (hereinafter referred to as film A), which had been cut into 5 cm x 5 cm in advance, was immersed in the undiluted stock solution, and cultured at 37 ° C for 24 hours. After culturing, the immersion original solution, with sterile saline, was diluted to 10 4 times 10-fold serial (hereinafter, abbreviated as 1 0 n times dilution).
- N a 4 Oxl 0 n xN no 0.1
- the composition containing the ionic complex of the example had both excellent antithrombotic properties over a long period of time and high antibacterial properties. This is because, in the composition containing the ionic complex of the example, (b) the water-insoluble ammonium salt strongly retains heparin or the heparin derivative on the blood contact surface of the medical device while (b) a) Ammonia salt soluble in water controls the release rate of heparin moderately, preventing the ionic complex from being too hydrophobic, and thus exhibits excellent antithrombotic properties over a long period of time. ) It is considered that the antibacterial property due to the water-soluble ammonium salt is also exerted.
- compositions containing the ionic complex of the comparative example had excellent antithrombotic and antibacterial properties over a long period of time.
- Heparin (35 parts by weight) was dissolved in ion-exchanged water (150 parts by weight), and then ethanol was added to the heparin aqueous solution.
- Heparin aqueous solution: ethanol] [70:30 (weight ratio) ).
- heparin was partially precipitated in the solution and the solution was suspended.
- the solution became a homogeneous solution by raising the temperature of the solution to 70 ° C.
- an ammonium salt solution was added dropwise thereto.
- the reaction precipitated immediately in solution.
- the precipitate was collected, washed thoroughly to remove unreacted heparin and ammonium salts.
- the residue was centrifuged to remove water and then freeze-dried to obtain the ionic complex (Example 4) used in the present invention. (Example 5)
- Example 5 Dissolve 18 parts by weight of didodecyldimethylammonium bromide (manufactured by Tokyo Kasei) and 72 parts by weight of dieicosanyl getyl ammonium bromide (manufactured by Tokyo Kasei) in 140 parts by weight of ethanol In the same manner as in Example 4, the ionic complex (Example 5) used in the present invention was obtained.
- Example 7 Dissolve 15 parts by weight of ditetradecyldimethylammonium bromide (manufactured by Tokyo Kasei) and 45 parts by weight of dieicosanyldimethylammonium bromide (manufactured by Tokyo Kasei) in 150 parts by weight of ethanol Then, in the same manner as in Example 4, the ionic complex (Example 7) used in the present invention was obtained. ⁇ ⁇
- Example 4 15 parts by weight of didodecyldimethylammonium bromide (manufactured by Tokyo Kasei) and 40 parts by weight of didecyldimethylammonium bromide (manufactured by Tokyo Kasei) were dissolved in 150 parts by weight of ethanol.
- An ionic complex (Comparative Example 4) was obtained in the same manner as in Example 4.
- Example 6 60 parts by weight of benzyldimethylsiloxane decylammonium bromide (manufactured by Tokyo Chemical Industry) was dissolved in 150 parts by weight of water, and the ionic complex (Comparative Example 6) was prepared in the same manner as in Example 4. ).
- Example 7 45 parts by weight of dioctyl decyldimethylammonium bromide (manufactured by Tokyo Chemical Industry) was dissolved in 150 parts by weight of ethanol, and the ionic complex (Comparative Example 7) was prepared in the same manner as in Example 4. Obtained.
- compositions containing the ionic complex obtained in Examples 4 to 7 and Comparative Examples 4 to 7 were evaluated by the following methods.
- a 0 ml diaphragm-type ventricular assist device (Toyobo assist device).
- a 100 ml blood bag is filled with physiological saline, and one end of each of the tubes connected to the inlet and outlet is connected to the blood bag, and the blood bag is placed in a 37 ° C water tank. And warmed.
- This ventricular assist device is connected to a special drive unit (Toyobo VCT—20) to generate a negative pressure of 80 mmHg, a positive pressure of 300 mmHg, and a flow rate of approx. It was driven under the condition of 7 1 / min.
- the physiological saline solution filled in the blood bag was changed every day so that the released heparin or heparin derivative or ammonium salt did not rejoin the evaluation tube. Under these conditions, the tube was driven for 2 weeks while periodically collecting tubes of a length required for evaluation. After gently washing the collected tubes with ion-exchanged water, the activity value of heparin remaining on the surface was measured by a test team using Palin S (manufactured by Daiichi Pure Chemicals). The results are shown in Table 3 below.
- a 0.2 wt% THF solution of the ionic complex of each of Examples 4 to 7 and Comparative Examples 4 to 7 was prepared and placed on the inner surface of a diaphragm-type artificial heart (Toyobo Co., Ltd.) having a stroke volume of 70 ml. Each was coated.
- a healthy adult goat was equipped with a ventricular assist device (an extracorporeal ventricular assist device in which a force neuron penetrated the skin and a blood pump was installed outside the body).
- the blood pump for the assisted artificial heart was introduced into the left atrium of the adult goat, and the blood feed neural was attached to the aorta of the adult goat via an artificial blood vessel.
- the inside of the blood pump of the ventilator was monitored daily, and if a thrombus had formed, the blood pump was removed from the blood removal and blood supply neura, and replaced with a new blood pump for evaluation. Antithrombotic properties were evaluated based on the number of days up to the point where thrombus occurred. The results are shown in Table 3 below.
- the composition containing the ionic complex of the present invention comprises a composition containing an ionic complex of heparin or a heparin derivative and only one type of ammonium salt, which is a conventional technique ( Compared with Comparative Examples 6 and 7), it has better antithrombotic properties.
- composition of the present invention provides superior antithrombotic properties over a longer period of time as compared with the compositions disclosed by the present inventors in Patent No. 3228409 (Comparative Examples 4 and 5). Can be.
- composition of the present invention contains an ionic complex formed from an organic cation mixture, which is a mixture of at least two kinds of ammonium salts, and heparin or a heparin derivative. It can provide antithrombotic properties.
- the composition of the present invention comprises a mixture of at least two ammonium salts, namely at least one (a) water-soluble ammonium salt and at least one (b) water-insoluble ammonium salt.
- a medical device can be provided with excellent antithrombotic and antibacterial properties over a long period of time.
- composition of the present invention comprises at least two kinds of ammonium salts, that is, an organic cation mixture which is a mixture with the above-mentioned specific ammonium salts (c) and (d), and an ion mixture of heparin or a heparin derivative.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60231209T DE60231209D1 (de) | 2001-06-05 | 2002-06-05 | Antithrombotische zusammensetzungen und diese enthaltende medizinische instrumente |
JP2003501386A JP4273965B2 (ja) | 2001-06-05 | 2002-06-05 | 抗血栓性組成物およびそれを有する医療用具 |
US10/479,596 US20040213818A1 (en) | 2001-06-05 | 2002-06-05 | Antithrombotic compositions and medical instruments containing the same |
EP02738623A EP1402871B1 (en) | 2001-06-05 | 2002-06-05 | Antithrombotic compositions and medical instruments containing the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001169978 | 2001-06-05 | ||
JP2001-169978 | 2001-06-05 | ||
JP2001-342335 | 2001-11-07 | ||
JP2001342335 | 2001-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002098344A1 true WO2002098344A1 (fr) | 2002-12-12 |
Family
ID=26616382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/005542 WO2002098344A1 (fr) | 2001-06-05 | 2002-06-05 | Compositions antithrombotiques et instruments medicaux contenant lesdites compositions |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040213818A1 (ja) |
EP (1) | EP1402871B1 (ja) |
JP (1) | JP4273965B2 (ja) |
DE (1) | DE60231209D1 (ja) |
WO (1) | WO2002098344A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9295763B2 (en) | 2011-08-19 | 2016-03-29 | Toyobo Co., Ltd. | Medical tube |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101035759B (zh) * | 2004-09-27 | 2011-06-15 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形 |
WO2013156861A2 (en) | 2012-04-17 | 2013-10-24 | University College Dublin, National University Of Ireland, Dublin | Methods and compounds for treating proliferative disorders and viral infections |
US9388127B2 (en) | 2012-04-17 | 2016-07-12 | University College Dublin, National University Of Ireland, Dublin | Thromboxane receptor antagonists |
EP2941249A4 (en) * | 2013-01-07 | 2016-09-28 | Univ Maryland | BIOCOMPATIBLE COATING COMPOSITIONS |
CN105073148B (zh) | 2013-04-12 | 2017-08-04 | 东丽株式会社 | 具有抗血栓性的人工血管 |
WO2015080176A1 (ja) | 2013-11-28 | 2015-06-04 | 東レ株式会社 | 抗血栓性材料 |
WO2015080177A1 (ja) | 2013-11-28 | 2015-06-04 | 東レ株式会社 | 抗血栓性材料 |
RU2646506C1 (ru) | 2014-02-12 | 2018-03-05 | Торэй Индастриз, Инк. | Искусственный кровеносный сосуд |
US10709822B2 (en) | 2015-03-31 | 2020-07-14 | Toray Industries, Inc. | Antithrombotic metallic material |
ES2858551T3 (es) | 2015-06-16 | 2021-09-30 | Atxa Therapeutics Ltd | Antagonistas del receptor de tromboxano |
US11000636B2 (en) | 2016-09-30 | 2021-05-11 | Toray Industries, Inc. | Copolymer and medical material containing the same |
RU2020114003A (ru) | 2017-09-29 | 2021-10-29 | Торэй Индастриз, Инк. | Антитромботический медицинский материал с применением никель-титанового сплава |
AU2019214612A1 (en) | 2018-01-30 | 2020-07-09 | Toray Industries, Inc. | Plain-weave fabric, method for manufacturing same, and stent graft |
CA3121617A1 (en) | 2019-01-30 | 2020-08-06 | Toray Industries, Inc. | Medical base material for indwelling cardiovascular device |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04197264A (ja) * | 1990-11-28 | 1992-07-16 | Terumo Corp | 抗血栓性医療材料の製造方法および抗血栓性医療材料を備えた医療用器具 |
JPH07108061A (ja) * | 1993-10-14 | 1995-04-25 | Mitsubishi Cable Ind Ltd | 抗血栓性複合体および医療用器具 |
JPH09169801A (ja) * | 1995-10-17 | 1997-06-30 | Terumo Corp | ヘパリン複合体およびそれを被覆した医療器具 |
JPH09187502A (ja) * | 1996-01-09 | 1997-07-22 | Toyobo Co Ltd | 抗血栓性、抗菌性組成物および医用材料 |
JPH11164882A (ja) * | 1997-12-05 | 1999-06-22 | Toyobo Co Ltd | 血液適合性組成物および医療用具 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4813341B1 (ja) * | 1969-06-13 | 1973-04-26 | ||
SE8200751L (sv) * | 1982-02-09 | 1983-08-10 | Olle Larm | Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter |
US5069899A (en) * | 1989-11-02 | 1991-12-03 | Sterilization Technical Services, Inc. | Anti-thrombogenic, anti-microbial compositions containing heparin |
ES2120961T3 (es) * | 1990-07-12 | 1998-11-16 | Sts Biopolymers Inc | Composicion anti-trombogena y/o anti-microbiana. |
JP4626005B2 (ja) * | 2000-01-27 | 2011-02-02 | 東洋紡績株式会社 | 血液適合性組成物およびそれを被覆した医療用具 |
-
2002
- 2002-06-05 DE DE60231209T patent/DE60231209D1/de not_active Expired - Lifetime
- 2002-06-05 EP EP02738623A patent/EP1402871B1/en not_active Expired - Fee Related
- 2002-06-05 US US10/479,596 patent/US20040213818A1/en not_active Abandoned
- 2002-06-05 WO PCT/JP2002/005542 patent/WO2002098344A1/ja active Application Filing
- 2002-06-05 JP JP2003501386A patent/JP4273965B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04197264A (ja) * | 1990-11-28 | 1992-07-16 | Terumo Corp | 抗血栓性医療材料の製造方法および抗血栓性医療材料を備えた医療用器具 |
JPH07108061A (ja) * | 1993-10-14 | 1995-04-25 | Mitsubishi Cable Ind Ltd | 抗血栓性複合体および医療用器具 |
JPH09169801A (ja) * | 1995-10-17 | 1997-06-30 | Terumo Corp | ヘパリン複合体およびそれを被覆した医療器具 |
JPH09187502A (ja) * | 1996-01-09 | 1997-07-22 | Toyobo Co Ltd | 抗血栓性、抗菌性組成物および医用材料 |
JPH11164882A (ja) * | 1997-12-05 | 1999-06-22 | Toyobo Co Ltd | 血液適合性組成物および医療用具 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1402871A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9295763B2 (en) | 2011-08-19 | 2016-03-29 | Toyobo Co., Ltd. | Medical tube |
Also Published As
Publication number | Publication date |
---|---|
US20040213818A1 (en) | 2004-10-28 |
EP1402871B1 (en) | 2009-02-18 |
EP1402871A4 (en) | 2005-12-28 |
JP4273965B2 (ja) | 2009-06-03 |
JPWO2002098344A1 (ja) | 2005-04-07 |
DE60231209D1 (de) | 2009-04-02 |
EP1402871A1 (en) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002098344A1 (fr) | Compositions antithrombotiques et instruments medicaux contenant lesdites compositions | |
US20160375180A1 (en) | Method for producing medical device and medical device | |
JP5685539B2 (ja) | 制御放出可能な抗菌剤を備えた医療デバイス | |
JP6373872B2 (ja) | 医療用具 | |
WO2000061205A1 (en) | Lubricious coatings for medical devices | |
WO2013027556A1 (ja) | 抗血栓性材料および医療用具 | |
US9956324B2 (en) | Medical material, and medical device using the medical material | |
JP4626005B2 (ja) | 血液適合性組成物およびそれを被覆した医療用具 | |
JP6456196B2 (ja) | 抗血栓性接着用組成物、ならびに該抗血栓性接着用組成物を利用した医療用具およびその製造方法 | |
EP2540325B1 (en) | Peptide based antimicrobial coating | |
JP3818684B2 (ja) | 抗血栓性医療用基材及びその製造方法 | |
JP6278731B2 (ja) | 抗血栓性医療材料、および該医療材料を利用した医療用具 | |
JP2014147639A (ja) | 医療用具 | |
JP4347927B2 (ja) | 抗血栓性医療用具の製造方法 | |
JP4258703B2 (ja) | 血液適合性組成物およびそれをコートした医療用具 | |
WO2015098764A1 (ja) | 抗血栓性医療材料、および該医療材料を利用した医療用具 | |
JP2002360686A (ja) | 抗菌性を有する抗血栓性組成物およびそれをコートした医療用具 | |
JP4691745B2 (ja) | 抗菌性抗血栓性材料のコーティング方法 | |
JP2003048840A (ja) | 抗菌性付与抗血栓性組成物およびそれをコートした医療用具 | |
WO2013136849A1 (ja) | 血液適合性材料および医療用具 | |
CN114848923A (zh) | 一种双模量多功能自适应型涂层、其应用和一种医用介入类导管 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003501386 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002738623 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002738623 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10479596 Country of ref document: US |